Published in PLoS One on July 10, 2012
Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr (2012) 0.98
Lactobacillus crispatus dominant vaginal microbiome is associated with inhibitory activity of female genital tract secretions against Escherichia coli. PLoS One (2014) 0.95
Plasma and mucosal HIV viral loads are associated with genital tract inflammation in HIV-infected women. J Acquir Immune Defic Syndr (2013) 0.94
Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1. J Acquir Immune Defic Syndr (2014) 0.91
Phase I randomized safety study of twice daily dosing of acidform vaginal gel: candidate antimicrobial contraceptive. PLoS One (2012) 0.87
Immunobiology of genital tract trauma: endocrine regulation of HIV acquisition in women following sexual assault or genital tract mutilation. Am J Reprod Immunol (2012) 0.84
Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS Res Hum Retroviruses (2015) 0.84
Innate immunity in the vagina (Part II): Anti-HIV activity and antiviral content of human vaginal secretions. Am J Reprod Immunol (2014) 0.81
Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease. Med Microbiol Immunol (2014) 0.80
IL-36γ Augments Host Defense and Immune Responses in Human Female Reproductive Tract Epithelial Cells. Front Microbiol (2016) 0.80
Innate Antibacterial Activity in Female Genital Tract Secretions Is Associated with Increased Risk of HIV Acquisition. AIDS Res Hum Retroviruses (2015) 0.79
How can we design better vaccines to prevent HIV infection in women? Front Microbiol (2014) 0.79
A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses (2012) 0.79
HIV, sexual violence and special populations: adolescence and pregnancy. Am J Reprod Immunol (2012) 0.75
Soluble Immune Mediators and Vaginal Bacteria Impact Innate Genital Mucosal Antimicrobial Activity in Young Women. Am J Reprod Immunol (2015) 0.75
Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women. Am J Reprod Immunol (2015) 0.75
Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep (2010) 14.85
Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS (2008) 4.21
Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol (2007) 3.10
Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis (2001) 2.49
Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29
Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis (2010) 2.25
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
A persistent(ly) enigmatic ecological mystery: bacterial vaginosis. J Infect Dis (2006) 1.83
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (2007) 1.75
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
Defense factors of vaginal lactobacilli. Am J Obstet Gynecol (2001) 1.68
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol (2006) 1.64
Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS (2009) 1.64
Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis (1991) 1.62
Chlamydia trachomatis in women: antibody in cervical secretions as a possible indicator of genital infection. J Infect Dis (1979) 1.60
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol (2004) 1.50
Interpreting the epidemiology and natural history of bacterial vaginosis: are we still confused? Anaerobe (2011) 1.50
Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol (2006) 1.48
Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun (2006) 1.40
Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci U S A (1999) 1.30
Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis (2005) 1.29
Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retroviruses (2008) 1.28
Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis. J Exp Pathol (Oxford) (1990) 1.25
Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol (2000) 1.25
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. J Infect Dis (2012) 1.17
Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr (2008) 1.16
Diagnosis and management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: summary of evidence reviewed for the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis (2011) 1.15
Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol (2010) 1.07
Immune activation in the female genital tract during HIV infection predicts mucosal CD4 depletion and HIV shedding. J Infect Dis (2011) 1.06
Molecular methods to describe the spectrum and dynamics of the vaginal microbiota. Anaerobe (2011) 1.05
The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob (2011) 1.04
Protective immunity to chlamydial genital infection: evidence from animal studies. J Infect Dis (2010) 1.03
In vitro inhibitory activity of human vaginal lactobacilli against pathogenic bacteria associated with bacterial vaginosis in Kenyan women. Anaerobe (2009) 1.02
Protective immunity in pig-tailed macaques after cervical infection with Chlamydia trachomatis. Sex Transm Dis (1991) 1.02
Mucosal immunity of the adolescent female genital tract. J Adolesc Health (2003) 0.98
Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry (2005) 0.97
Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol (2006) 0.90
Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread. Virol J (2009) 0.85
World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. I. A multicenter cross-sectional study of menarche. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health Care (1986) 0.82
Female genital tract immunization: evaluation of candidate immunoadjuvants on epithelial cell secretion of CCL20 and dendritic/Langerhans cell maturation. Vaccine (2006) 0.82
Adolescent menstrual irregularity. J Reprod Med (1984) 0.81
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.05
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79
Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol (2008) 2.73
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62
Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis (2007) 2.57
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative. Pediatr Blood Cancer (2012) 2.07
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis (2011) 1.94
Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell (2004) 1.81
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
Motor stereotypies in children with autism and other developmental disorders. Dev Med Child Neurol (2009) 1.78
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (2007) 1.75
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother (2004) 1.69
Extreme heterogeneity in the molecular events leading to the establishment of chiasmata during meiosis i in human oocytes. Am J Hum Genet (2004) 1.67
Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum (2012) 1.66
Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol (2012) 1.65
Diffusion-tensor imaging implicates prefrontal axonal injury in executive function impairment following very mild traumatic brain injury. Radiology (2009) 1.65
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol (2006) 1.64
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Unintentional injuries in the home in the United States Part I: mortality. Am J Prev Med (2005) 1.59
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Herpes simplex virus triggers activation of calcium-signaling pathways. J Cell Biol (2003) 1.58
Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis (2003) 1.58
Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol (2004) 1.58
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis (2005) 1.54
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis (2007) 1.48
Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. Am J Epidemiol (2008) 1.48
Facilitated psychiatric advance directives: a randomized trial of an intervention to foster advance treatment planning among persons with severe mental illness. Am J Psychiatry (2006) 1.47
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One (2010) 1.46
Incident cardiovascular disease events in metabolically benign obese individuals. Obesity (Silver Spring) (2011) 1.45
Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant (2011) 1.40
Femoral vascular closure device use, bivalirudin anticoagulation, and bleeding after primary angioplasty for STEMI: results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv (2014) 1.40
Impact of surveillance stool culture guided selection of antibiotics in the management of pediatric small bowel transplant recipients. Pediatr Transplant (2006) 1.39
Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis. J Neurosci (2006) 1.34
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer (2009) 1.34
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol (2008) 1.32
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother (2005) 1.31
Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis (2005) 1.29
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol (2002) 1.27
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol (2008) 1.26
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry. J Biol Chem (2005) 1.24
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther (2009) 1.24
PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther (2009) 1.24
Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl (2002) 1.23
A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J Virol (2006) 1.22
Robust detection of traumatic axonal injury in individual mild traumatic brain injury patients: intersubject variation, change over time and bidirectional changes in anisotropy. Brain Imaging Behav (2012) 1.20
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol (2007) 1.19
ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res (2006) 1.15
Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control (2011) 1.15
Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer (2009) 1.14
Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis (2011) 1.14
The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med (2012) 1.13
Soccer heading is associated with white matter microstructural and cognitive abnormalities. Radiology (2013) 1.12
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
The cervical microbiome over 7 years and a comparison of methodologies for its characterization. PLoS One (2012) 1.11
Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. Mol Biol Cell (2007) 1.10
The fetal Doppler mechanical PR interval: a validation study. Fetal Diagn Ther (2003) 1.09
Whole brain approaches for identification of microstructural abnormalities in individual patients: comparison of techniques applied to mild traumatic brain injury. PLoS One (2013) 1.09
Research gaps in defining the biological link between HIV risk and hormonal contraception. Am J Reprod Immunol (2014) 1.08
Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant (2003) 1.08
Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes (2012) 1.08
Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08
Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One (2011) 1.08
Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. J Am Chem Soc (2004) 1.07
Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis (2007) 1.07
NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother (2003) 1.07
Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J Virol (2013) 1.07
More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One (2013) 1.07
Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. BMC Infect Dis (2009) 1.07
Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis (2006) 1.06
Sequencing and analysis of fungal rRNA operons for development of broad-range fungal PCR assays. Appl Environ Microbiol (2009) 1.06
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Clinical decision making and views about psychiatric advance directives. Psychiatr Serv (2006) 1.05
Changes in brown adipose tissue in boys and girls during childhood and puberty. J Pediatr (2011) 1.04